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SARS coronavirus (SARS-CoV) encodes several unique group-specific open reading frames (ORFs) relative
to other known coronaviruses. To determine the significance of the SARS-CoV group-specific ORFs in virus
replication in vitro and in mice, we systematically deleted five of the eight group-specific ORFs, ORF3a, OF3b,
ORF6, ORF7a, and ORF7b, and characterized recombinant virus replication and gene expression in vitro.
Deletion of the group-specific ORFs of SARS-CoV, either alone or in various combinations, did not dramat-
ically influence replication efficiency in cell culture or in the levels of viral RNA synthesis. The greatest
reduction in virus growth was noted following ORF3a deletion. SARS-CoV spike (S) glycoprotein does not
encode a rough endoplasmic reticulum (rER)/Golgi retention signal, and it has been suggested that ORF3a
interacts with and targets S glycoprotein retention in the rER/Golgi apparatus. Deletion of ORF3a did not alter
subcellular localization of the S glycoprotein from distinct punctuate localization in the rER/Golgi apparatus.
These data suggest that ORF3a plays little role in the targeting of S localization in the rER/Golgi apparatus.
In addition, insertion of the 29-bp deletion fusing ORF8a/b into the single ORF8, noted in early-stage
SARS-CoV human and civet cat isolates, had little if any impact on in vitro growth or RNA synthesis. All
recombinant viruses replicated to wild-type levels in the murine model, suggesting that either the group-
specific ORFs play little role in in vivo replication efficiency or that the mouse model is not of sufficient quality
for discerning the role of the group-specific ORFs in disease origin and development.
Coronavirus infections are associated with severe diseases of
the lower respiratory and gastrointestinal tract in humans and
animals, yet little is known about the underlying molecular
mechanisms governing virulence and pathogenesis. Among the
human coronaviruses, severe acute respiratory disease corona-
virus (SARS-CoV) infection is an attractive model to study the
molecular basis for pathogenesis, given its robust in vitro
growth characteristics, reverse genetics, animal models, wealth
of clinical data, and several solved replicase and group-specific
protein structures (15, 20, 31, 34, 36, 37, 40, 46, 47, 57, 69).
SARS-CoV infection results in severe acute respiratory dis-
ease, pneumonia, and in about 10% of the cases, death (14,
31). With over 8,000 probable cases and 774 deaths reported
worldwide before intervention strategies contained the further
spread of this pathogen, mortality rates exceeded 50% in el-
derly populations. Survivors display long-term lung and cardiac
complications (24, 44). In comparison to other known human
coronaviruses, SARS-CoV infection is highly pathogenic and
the genetic factors responsible for the increased virulence of
the SARS-CoV are not known. Obviously, identifying alleles
that influence pathogenic outcomes provides a rational ap-
proach for the development of attenuated SARS-CoV strains,
either for use in laboratory settings or as seed stocks for live-
or killed-virus vaccines.
Human coronaviruses, members of the Nidovirus order, have
been divided into several genogroups (7). The group I coro-
naviruses include human coronavirus 229E (HCV-229E),
which is typically associated with the common cold. A second
group I coronavirus, HCV-NL63, causes more severe lower
respiratory tract disease in infants, children, and adults, world-
wide (18, 64), and may also be associated with Kawasaki dis-
ease (16). The group II human coronaviruses include HCV-
OC43, which has typically been associated with common colds
in winter and occasional lower respiratory tract infections in
children and adults, and the recently described HKU1, which
was identified in two adults with pneumonia (68). However, the
overall epidemiology and severity of HKU1 infection in hu-
mans remains undefined. Phylogenetic analyses have suggested
that SARS-CoV either represents the prototype group IV
coronavirus or can be classified as an early split-off of group II
(36, 48, 54). SARS-CoV-like viruses have been isolated from
civet cats, raccoon dogs, and pigs, but the civet cat is a likely
reservoir (22). Molecular evolutionary studies on isolates ob-
tained from different stages in the outbreak have implicated
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changes in open reading frame 1a (ORF1a), the spike (S)
glycoprotein, and various group-specific ORFs (ORF3a and
ORF8) as being associated with increased virulence, transmis-
sion, and pathogenicity during the epidemic (9). In civet cats
and early-stage human isolates, ORF8 is encoded as a single
contiguous ORF, while in middle/late-phase epidemic, strains
contain a 29-nucleotide (nt) deletion that produces two ORFs,
designated ORF8a and ORF8b (22).
The SARS-CoV virion contains a single-stranded, positive-
polarity, 29,700-nucleotide-long RNA genome bound by the
nucleocapsid (N) protein. The capsid is surrounded by a lipid
bilayer containing at least three structural proteins, designated
S, M, and E. The 180-kDa S glycoprotein interacts with an
angiotensin-2-converting enzyme receptor to mediate entry
into cells (70). In addition to the 23-kDa M glycoprotein, the E
protein may be essential for efficient virion production (39).
The SARS-CoV genome contains nine ORFs, the first of
which encodes the viral replicase proteins required for sub-
genomic- and genome length RNA synthesis and virus repli-
cation (36, 48, 50). Based on studies with other coronaviruses,
it is likely that SARS-CoV uses transcription attenuation to
synthesize both full-length and subgenomic-length negative-
strand RNAs containing antileader sequences, which then
function as the templates for the synthesis of like-sized
mRNAs (5, 51, 52). ORFs 2 through 8 are encoded in seven
subgenomic mRNAs synthesized as a nested set of 3 cotermi-
nal molecules in which the leader RNA sequences, encoded at
the 5 end of the genome, are joined to body sequences at
distinct transcription regulatory sequences which contain a
highly conserved consensus sequence (CS) (54, 63, 74). The
SARS-CoV CS is ACGAAC (36, 48, 54, 63, 74). The virion
structural genes S, E, M, and N are encoded in mRNA tran-
scripts 2, 4, 5, and 9, respectively, while the group-specific
ORFs are encoded on mRNAs 3, 6, 7, 8, and 9. Interspaced
among the SARS-CoV structural genes are group-specific
genes, ORF3a/b, ORF6, ORF7a/b, ORF8a/b, and ORF9b,
which are not conserved in other coronaviruses and whose
functions in replication and pathogenesis are generally un-
known (36, 48, 54). Among these, ORF3a localizes in rough
endoplasmic reticulum (rER)/Golgi compartments, interacts
with the S and M glycoproteins, and is incorporated into viri-
ons, suggesting that it may function in virion maturation and
release (28). However, group-specific ORFs from other coro-
naviruses like mouse hepatitis virus (MHV), feline infectious
peritonitis virus (FIPV), and transmissible gastroenteritis virus
(TGEV) are not essential for efficient in vitro replication (12,
13, 66) but often attenuate virulence in vivo (12, 13, 23). The
development of a molecular clone for the SARS-CoV provides
a useful tool to study the role of the SARS-CoV group-specific
ORFs in replication and pathogenesis (74).
A relevant animal disease model for SARS-CoV pathogen-
esis has been difficult to identify. A variety of animal models
for SARS-CoV have been reported, and infection is associated
with mild acute disease in the macaque, ferret, cat, BALB/c
and C57BL/6 mice, and hamster with little, if any, mortality
(19, 21, 37, 38, 46, 49, 56, 65). Animal models reminiscent of
late-stage human diseases have not been established. In young
BALB/c mice, peak virus replication occurred on day 2 with
virus clearance in a week in the absence of any clinical disease
or pathological lesions. Viral antigen and RNA were detected
in bronchiolar epithelial cells (56). With a molecular cDNA
clone of the SARS-CoV genome, we systematically deleted
several of the group-specific ORFs of the SARS-CoV genome
and engineered recombinant viruses encoding a full-length
ORF8. Here, we describe the replication kinetics and pheno-
type of these mutants in vitro and in BALB/c mice. Our data
indicate that the SARS-CoV group-specific ORF3a, ORF3b,
ORF6, ORF7a, and ORF7a/b can be deleted singly or in com-
bination and that ORF8a and ORF8b can be joined into a
full-length ORF8 with minimal impact on the kinetics of virus
replication in vitro and in vivo. The development of a more
relevant animal model for discerning the role of the group-
specific ORFs in virulence and pathogenesis is likely needed.
MATERIALS AND METHODS
Virus and cells. The Urbani and infectious clone (ic) recombinant virus ic-
SARS strains of SARS-CoV (AY278741) were propagated on Vero E6 cells in
Eagle’s minimal essential medium supplemented with 10% fetal calf serum,
kanamycin (0.25 g/ml), and gentamicin (0.05 g/ml) at 37°C in a humidified
CO2 incubator. For virus growth, cultures of Vero E6 cells were infected at a
multiplicity of infection (MOI) of 5 for 1 h and the monolayer washed two times
with 2 ml of phosphate-buffered saline (PBS) and overlaid with complete mini-
mal essential medium. Virus samples were harvested at different times postin-
fection and titered by plaque assay in 60-mm2 dishes. Plaques were visualized by
neutral red staining and counted at 48 h. All virus work was performed in a
biological safety cabinet in a biosafety level 3 (BSL3) laboratory containing
redundant exhaust fans. Personnel were double-gloved and dressed in Tyvek
suits with full hoods and face shields. Powered air-purifying respirators with
high-efficiency particulate air and organic vapor filters were used to provide a
positive-pressure environment within the hoods.
Construction of recombinant viruses. Software programs were used to design
primer pairs for the systematic removal of the various group-specific ORFs.
Briefly, to delete the N-terminal one-half of ORF3a, sense and antisense primer
sets #44 (5-TGATCCTCTGCAACCTGAGC-3) and SARS Mu1 (5-ATCGA
TGGCGCGCCCACCTGCTAAGTTCGTTTATGTGTAATGTAATTTG-3)
and primer sets #3-X5 (5-TTAATTAATTAATTTGTTCGTTTATTTAAAA
CAACA-3) and SARS Mu2 (5-GGCGCGCCATCGATTTAATTAAGGAAG
TGCAAATCCAAGAACCC-3) were used to amplify products flanking nucle-
otides 25,297 and 25,686, respectively, in the SARS-CoV genome. PCR products
were digested with AarI and subcloned by TA cloning into pTOPO-PCR XL for
sequencing. Amplicons containing the correct sequence were digested with Swa1
and NdeI and ligated into SwaI-NdeI-digested SARS F subclone, systematically
removing nucleotides 25,297 through 25,686 and introducing a multiple cloning
site at25,296 containing an AarI, AscI, ClaI, and PacI site. To delete ORF3a/b,
the #44/Mu1 amplicon was ligated with an amplicon generated with #3-X5 and
SARS Mu3 (5-CACCTGCTAAACGAACTTATGTACTCATTCGTTTCGG-
3). These PCR products were digested with AarI, ligated, and subcloned by TA
cloning to pTOPO PCR-XL for sequencing. Amplicons were digested with SwaI
and NdeI and introduced back into the SwaI-NdeI-digested SARS F subclone,
systematically deleting nucleotides 25,297 through 26,142 in the SARS-CoV
genome. To delete ORF6, sense and antisense primer sets #44 and SARS Mu4
(5-CACCTGCCATGTTCGTTCTGTTGTCACTTACTGTACTAGC-3) and
SARS Mu5 (5-CACCTGCAAAACGAACATGAAAATTATTCTCTTCCTG
AC-3) and 3-X5 were used to amplify products flanking nucleotides 27,103 and
27,266, respectively. The PCR products were digested with AarI, ligated, and
subcloned into pTOPO PCR-XL vectors for sequencing. The SwaI-NdeI frag-
ment containing the 192-bp deletion (nucleotides 27,102 through 27,293) of
ORF6 was subcloned into SARS F as described previously. To delete ORF7a/b,
primer sets #47 (5-GTGCTTGCTGTTGTCTACAG-3) and SARS Mu6 (5-
ATCGATCACCTGCCATGTTCGTTTTATGGATAATCTAACTCCATAGG
TTC-3) and SARS Mu7 (5-ATCGATTTAATTAAGAGCTCACTTTAATTG
ACTTCTATTTGTG-3) and SARS Ng1() (5-CTTTGCTCTCAAGCTGGT
TC-3) were used to generate amplicons flanking nucleotides 27,304 through
27,671 in the SARS-CoV genome. The amplicons were digested with Aar1,
subcloned, and sequenced. An AvrII-cut amplicon was purified and ligated back
into the SARS F cDNA clone, systematically deleting nucleotides 27,304 through
27,671 and inserting an AarI, ClaI, and PacI multiple cloning site in the SARS-
CoV genome. To generate a recombinant virus encoding the 29 bp that are
present in early-stage isolates (SZ16 ORF8), primer pairs #47 and Mu29()
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(5-NNNCACCTGCTCAGGTTGGTAACCAGTAGGACAAGGATCTTCAA
GCACATGAG-3) and Ng1() and Mu29() (5-CACCTGCTTACCAACC
TGAATGGAATATAAGGTACAACACTAGGGGTAATAC-3) were used
to amplify cDNAs spanning the 29-nt deletion in SARS-CoV ORF8, systemat-
ically introducing 29 nucleotides from the SZ16 ORF8. The two PCR fragments
were digested with AarI, ligated, and cloned into TA cloning vectors. Following
sequence analysis, the full-length ORF8 was inserted into the SARS F clone by
using AvrII sites.
Assembly of full-length cDNAs. The SARS A through F inserts were digested,
separated through 0.8% agarose gels, visualized with a Darkreader Lightbox
(Claire Chemical), excised, and purified using the QIAEX II DNA purification
kit. The SARS AB, CD, and EF fragments were ligated overnight and the
products isolated (73, 74). The SARS AB, CD, and EF fragments were
ligated overnight at 4°C, phenol-chloroform extracted, and precipitated in iso-
propyl alcohol. Full-length transcripts were generated in vitro as described by the
manufacturer (mMessage mMachine; Ambion) with certain modifications. To
produce full-length capped SARS N gene transcripts, 1 g of plasmid DNA
encoding the SARS N gene was PCR amplified using forward primer (5-NNG
GCCTCGATGGCCATTTAGGTGACACTATAGATGTCTGATAATGGA
CCCCAATC-3) and reverse primer (5-NNNTTTTTTTTTTTTTTTTTTTTT
TTTTTATGCCTGAGTTGAATCAGCAG-3) and the amplicons purified from
gels. Full-length, polyadenylated N gene transcripts were transcribed by SP6
RNA polymerase with a 2:1 ratio of cap analog to GTP (Ambion, Austin, TX),
mixed with full-length transcripts, and electroporated into cells as described in
the next section.
Transfection of full-length transcripts. RNA transcripts were added to 800 l
of the Vero E6 cell suspension (8.0 106) in an electroporation cuvette, and four
electrical pulses of 450 V at 50 F were given with a Gene Pulser II electropo-
rator (Bio-Rad) similar to protocols previously described by our laboratory (73,
74). The presence of full-length cDNAs and transcripts was verified by separation
on agarose gels and visualization by UV light. The transfected Vero cells were
seeded in a 75-cm2 flask and incubated at 37°C for 2 days. Viruses were plaque
purified in Vero E6 cells and stock grown in 75-cm2 flasks.
PCR amplification of leader-containing transcripts and PCR genotyping.
Leader-containing amplicons were obtained from wild-type, icSARS-CoV, and
various recombinant-virus-infected cells using primers at the 3 end of the ge-
nome (primer 3; 5-TTTTTTTTTTTTTTTTTTTTTGTCATTCTCCTAAGA
AGC-3) for reverse transcription (RT) and a second set of primers for PCR
amplification of the SARS leader RNA sequence (5-AAAGCCAACCAACCT
CGATC-3). Leader-containing amplicons were excised from gels, subcloned
into TOPOII vectors, and sequenced using appropriate primers. Genotyping of
wild-type and recombinant SARS-CoV was accomplished using sets of primer
pairs spanning different portions of the 3 end of the genome. Positive-sense
primers #44, #45, #46, and #50 were used to genotype viruses containing
deletions in ORF3a, ORF3b, and ORF6, while primer sets #47, #48, and #51
were used to genotype recombinant viruses containing deletions in ORF7a/b and
those encoding a full-length civet cat SZ16 ORF8. For PCR genotyping, anti-
sense primers included either SARS E() or ORF8b() for initial reverse
transcription and then PCR amplification of amplicons spanning the various
deletion mutations in the SARS-CoV genome.
Northern blot analysis. Cultures of Vero E6 cells were inoculated with the
wild-type SARS-CoV Urbani strain and various recombinant viruses at an MOI
of 1.0 and incubated for 1 h at 37°C. At 12 h postinfection, intracellular RNA was
isolated using RiboPure reagents as directed by the manufacturer (Ambion,
Austin, TX). mRNA was isolated using Oliogtex mRNA spin column reagents
according to the manufacturer’s directions (QIAGEN, Valencia, CA). The
mRNA was treated with glyoxal and separated on agarose gels using Northern-
Max-Gly according to the manufacturer’s directions (Ambion, Austin, TX). The
RNA was transferred to a BrightStar-Plus membrane (Ambion) for 4 to 5 h and
the RNA cross-linked to the membrane with UV light. The blot was prehybrid-
ized and probed with an N-gene-specific oligodeoxynucleotide probe (5-CTT
GACTGCCGCCTCTGCTbTbCCCTbCTbGCb-3), where biontinylated nucleo-
tides are designated with a superscript b. Blots were hybridized overnight and
washed with low- and high-stringency buffers as recommended by the manufac-
turer. Filters were incubated with streptavidin-AP, washed, and then incubated
with the chemiluminescent substrate CDP-STAR. The blots were overlaid with
film and developed.
Confocal and fluorescent imaging. Antiserums were prepared in mice using
Venezuelan equine encephalitis (VEE) virus replicon particles (VRPs) express-
ing either the SARS-CoV S, N, or ORF3a proteins. Consensus sequences of the
SARS S glycoprotein, N protein, and ORF3a were inserted into the pVR21 VEE
replicon vector by overlapping-extension PCR using the SARS-CoV and VEE-
specific primer pairs and PCR conditions previously described by our laboratory
(3). VRPs encoding the SARS-CoV S glycoprotein, N protein, or ORF3a protein
were produced as previously described. The VRPs were inoculated into the
footpads of 4-week-old mice at 0 and 30 days postinfection (priming and booster)
and serum harvested 2 weeks postboost (25, 26). The production and charac-
terization of guinea pig antiserum directed against the SARS-CoV replicase nsp8
protein has previously been reported (45).
For fluorescent microscopy, Vero cells were grown on glass coverslips and
infected with SARS-CoV or various deletion mutants at an MOI of 5.0 PFU/cell.
Cells were infected for 12 h and rinsed with PBS. The infected cells were fixed
in ice-cold 100% methanol overnight, washed with PBS, and blocked in PBS
containing 5% bovine serum albumin (BSA). Cells were washed with PBS con-
taining 1% BSA, 0.05% NP-40, and 2% normal goat serum and the coverslips
incubated with primary antibody diluted 1:1,000 in PBS containing 1% BSA,
0.05% NP-40, and 2% normal goat serum. Secondary antibody was fluorescein
isothiocyanate-conjugated anti-mouse antibody diluted 1:1,000 in PBS contain-
ing 1% BSA, 0.05% NP-40, and 2% normal goat serum. Coverslips were washed,
mounted, and visualized with a Nikon Microphot FXA Upright fluorescence
microscope.
Western blot analysis. Twelve hours postinfection, Urbani, icSARS-CoV,
icSARS ORF3a, and ORF6 deletion-virus-infected cells were washed in 1
PBS and lysed in buffer containing 20 mM Tris-HCl (pH 7.6), 150 mM NaCl,
0.5% deoxycholine, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), and
postnuclear supernatants added to an equal volume of 5 mM EDTA and 0.9%
SDS, resulting in a final SDS concentration of 0.5%. Samples were then heat
inactivated for 30 min at 90°C in the BSL3 laboratory prior to removal. At the
BSL2 laboratory, samples were again heat inactivated for 30 min at 90°C before
use. Equivalent sample volumes were loaded onto 4 to 20% Criterion gradient
gels (Bio-Rad) and transferred to a polyvinylidene difluoride membrane (Bio-
Rad). Blots were probed with polyclonal mouse antisera directed against VRP-
expressed ORF3a diluted 1:200 and developed using enhanced chemilumines-
cence reagents (Amersham Biosciences).
To determine whether convalescent human sera could detect the ORF3a
protein, equal volumes of lysate from cells infected with VEE-VRP expressing
ORF3a were loaded onto 4 to 20% gradient Criterion gels (Bio-Rad) and
transferred to a polyvinylidene difluoride membrane (Bio-Rad). Blots were
probed with convalescent human serum 1128 diluted 1:2,000 and developed
using enhanced chemiluminescence reagents (Amersham Biosciences).
SARS inoculation of mice. Six-week-old female BALB/c mice (Charles River
Laboratories) were anesthetized with ketamine (1.3 mg/mouse) mixed with xy-
lazine (0.38 mg/mouse) that was administered by intraperitoneal injection in a
50-l volume. Each mouse was intranasally inoculated with 50 l of PBS con-
taining virus at a concentration of 2  105 PFU/ml of virus. Five animals were
used for each test virus. At two days, the right lung was removed and frozen at
70°C for later determination of viral titers. Half of the left lung was placed into
Trizol reagent (Invitrogen) for RNA extraction. The second half of the left lung
was fixed in 4% paraformaldehyde in PBS (pH 7.4) for at least 7 days prior to
paraffin embedding and sectioning for histopathological analysis (56). For virus
titrations, lungs were weighed and homogenized in 4 equivalent volumes of
diluent [PBS with 1% FC(II), 1 mM Ca2, and 1 mM Mg2] to generate a 20%
solution. The cell suspension was centrifuged at 13,000 rpm for 5 min and the
clarified supernatant serially diluted in PBS, and 200-l volumes of each dilution
were placed on a monolayer of Vero cells in 60-mm dishes. Following 1-h
incubation at room temperature, cells were overlaid with 1% agarose containing
complete medium. Two days later, plates were stained with neutral red and the
plaques visualized and counted.
Six-week-old female BALB/c mice were also inoculated with wild-type Urbani
or icSARS-CoV SZ16 ORF8 as previously described. Groups of four animals
were sacrificed on days 2, 4, and 7 as described earlier to determine if the
incorporation of a full-length ORF8 was associated with increased pathogenesis
or persistence. As described earlier, lungs were weighed and homogenized in
four volumes of diluent and titered by plaque assays as previously described.
RESULTS
Isolation of recombinant viruses. The SARS-CoV genome
has been cloned as a panel of cDNAs (SARS A through F) that
can be systematically assembled into full-length cDNA from
which full-length infectious transcripts can be derived. The
SARS-CoV F subclone encodes the SARS group-specific
ORFs. Using standard recombinant DNA approaches, we sys-
tematically deleted ORF3a (icSARS ORF3a), ORF6 (icSARS
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ORF6), and ORF7a/b (icSARS ORF7a/b) using PCR and
primer pairs encoding an AarI class IIS restriction endonucle-
ase site that allows for the seamless ligation of fragments flank-
ing a region targeted for deletion (74). A third set of mutants
lacking both ORF3a/b (icSARS ORF3a/b) and ORF3a/b and
ORF 6 (icSARS ORF3&6) was also constructed. Genome
organization of the mutants is shown in Fig. 1. SARS-CoV F
subclones encoding the various deletions were confirmed by
sequencing. The inserts were isolated after digestion with
restriction endonucleases BglI and Not1 and ligated to the
SARS-CoV A through E inserts. The full-length cDNA was
used as template for in vitro transcription and the RNA elec-
troporated into Vero cells for the recovery of recombinant
viruses.
In vitro growth characteristics. Cultures of Vero cells were
transfected with full-length transcripts lacking ORF3a, ORF6,
or ORF7a/b or the various combination mutations (icSARS
ORF3a/b, icSARS ORF3&6). Within 24 to 36 h posttrans-
fection, all transfected cultures displayed clear evidence of SARS-
associated cytopathology, cell rounding, and death. Supernatants
were harvested and passaged onto fresh cultures, resulting in
extensive cytopathology, cell rounding, and death within 36 h
postinfection. Plaque purified stocks were obtained, and RT-PCR
was used to demonstrate that each recombinant virus contained
the appropriate genotype (Fig. 2A and B). PCR products were
subcloned and sequenced, providing further verification of
each particular deletion or insertion in the recombinant ge-
nome (Fig. 2C). Plaque phenotype was similar among the
panel of recombinant viruses and wild-type Urbani (data not
shown).
Vero cells were inoculated with the panel of wild-type and
recombinant viruses at an MOI of 1.0, and virus samples were
harvested at various times postinfection. Consistent with re-
ports describing other coronaviruses lacking group-specific
ORFs, recombinant viruses replicated as efficiently as wild-
type virus, approaching titers of 107 PFU/ml within 24 h postin-
fection. Deletion of ORF3a resulted in the greatest reduction
of virus yields, about a 0.5 to 1 log reduction in Vero, MA104,
and Caco2 cells (Fig. 3). Other recombinants grew as efficiently
as wild-type virus. As earlier studies have implicated ORF3a as
FIG. 1. Genome organization of SARS-CoV recombinant viruses. The typical genome organization of the SARS-CoV includes a 21-kb
replicase encoded in ORF1a and ORF1b; the structural genes S (ORF2), E (ORF4), M (ORF5), and N (ORF9); and the group-specific ORFs
3a (X1), 3b (X2), 6(X3), 7a(X4)/b, 8a/b(X5), and 9b. Among SARS-CoV isolates obtained from animals or early-phase human cases, ORF8a/b
is fused into a single contiguous ORF8 by the presence of 29 nucleotides that are deleted in middle/late-phase epidemic strains like Urbani and
Tor-2. As described in the Materials and Methods, various SARS-CoV group-specific ORFs were deleted, either individually or in combinations.
The icSARS-CoV ORF3a lacks ORF3a, icSARS-CoV ORF6 lacks ORF6, and icSARS-CoV ORF7a/b lacks ORF7a/b, while icSARS-CoV
ORF3a/b and icSARS-CoV ORF3&6 lack ORF3a/b and ORF3a/b/ORF6, respectively. The recombinant virus icSARS-CoV SZ16 ORF8
contains a full-length ORF8, produced by the insertion of the 29 nt that are present in animal and early-phase human cases that fuses ORF8a
and -8b into a single ORF. Recombinant cDNAs containing the group-specific ORF deletions or insertions were confirmed by sequence analysis
and used to assemble full-length cDNAs for the recovery of recombinant SARS-CoV. TRS, transcription regulatory sequence.
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a structural protein (28), these results suggest that ORF3a is
not absolutely required for particle formation but may reduce
the efficiency of packaging and release. Alternatively, over-
expression of ORF3b may also mitigate a deleterious pheno-
type in the icSARS-CoV ORF3a mutant. Consistent with this
interpretation, deletion of ORF3a/b resulted in increased virus
titers when compared with the ORF3a deletion virus alone,
suggesting that the reduction in icSARS-CoV ORF3a virus
yields might be associated with increased ORF3b expression
resulting from the movement of ORF3b to the 5 end of
mRNA 3 (Fig. 3). The most debilitated virus, however, had
deletions excising ORF3a/b and ORF6, which displayed about
a 1 to 1.5 log reduction in titer when compared with wild-type
viruses (Fig. 3). These data indicate that the group-specific
ORFs 3a, 3b, 6, 7a, and 7b are not essential for replication in
cell culture, similar to earlier reports regarding the roles of
group-specific ORFs in the replication of other coronaviruses
(12, 13, 71).
Genome organization and RNA synthesis. SARS-CoV en-
codes both full-length and subgenomic-length mRNAs during
infection, and these RNAs are arranged in the form of a nested
set from the 3 end of the genome. Consequently, deletions of
various ORFs are expected to cause a reduction in the size of
all subgenomic transcripts that are upstream of the deletion.
To assess the impact of group-specific ORF deletion on SARS-
CoV RNA synthesis, cultures of Vero cells were inoculated
with various recombinant or wild-type viruses and intracellular
RNA harvested for Northern blot analysis (Fig. 4). Using a
probe specific for the nucleocapsid gene, wild-type- and icSARS-
CoV-infected cultures expressed both full-length RNAs and
the expected eight subgenomic mRNAs. Deletion virus tran-
scripts were characterized by the loss of specific transcripts
encoding the particular ORF deleted from each recombinant
virus and typified by the reduction in the size of the larger
mRNAs, like mRNA 2 encoding the S glycoprotein. As ex-
pected, viruses lacking several ORFs displayed larger-size re-
ductions in mRNA 2, as well as the loss of specific mRNAs
encoding the deleted ORF in each recombinant virus. Consis-
tent with earlier reports with MHV group-specific deletion
mutants, we have not seen a major alteration in the relative
FIG. 2. Genotype characterization of recombinant viruses. Cul-
tures of Vero cells were electroporated with full-length transcripts
derived from different recombinant full-length cDNAs. Virus progeny
were harvested between 24 and 36 h posttransfection and plaque
purified and stocks generated for future studies. Cultures of cells were
infected with stock viruses and intracellular RNA harvested at 12 h
postinfection. Using various primer pairs that span the deletions, re-
combinant viruses were genotyped by RT-PCR (panels A and B).
Primer location and expected sizes of PCR amplicons are shown in
panel C. Primer pairs #44, #45, and #46 and SARS CoV E() were
used in panel A, while primer pairs #47 and 48 and SARS-CoV
ORF8b() were used in panel B. These data confirm that the dele-
tions inserted into the component clones were found in the appropri-
ate recombinant viruses. WT, wild type.
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molar ratios of the genomic or upstream subgenomic mRNAs
following deletion.
We also examined the sites of leader/body mRNA fusion in
the recombinant viruses. In each case, subgenomic mRNAs
initiated at the appropriate upstream CS site, even in those
recombinant viruses that had deleted ORFs, consistent with
the notion that a functional transcriptional regulatory se-
quence consisted primarily of upstream and consensus se-
quences with minor contributions of downstream sites (data
not shown).
A VEE replicon particle (VRP-ORF3a) expressing SARS
ORF3a was constructed and used to infect Vero cells as de-
scribed in the Materials and Methods. Using the convalescent
antiserum from a human patient infected with SARS-CoV
(#1128), expression of ORF3a from VRP-ORF3a-infected
Vero cells was demonstrated, confirming earlier reports that
antiserum from human patients detects ORF3a (Fig. 5A). The
VRPs were then used to inoculate mice at 0 and 28 days (prime
and boost), and ORF3a-specific antiserum was harvested 2
weeks postboost. Cultures of Vero cells were infected with
icSARS-CoV, wild-type Urbani SARS-CoV, icSARS-CoV
ORF3a, and icSARS-CoV ORF6, and proteins were iso-
lated for Western blot analysis at 12 h postinfection. Proteins
were separated on polyacrylamide gels and probed with anti-
serum raised against ORF3a. As expected, ORF3a was clearly
evident as a predominant 30-kDa glycoprotein in Urbani
SARS-CoV, icSARS-CoV, and icSARS-CoV ORF6 dele-
tion-virus-infected cultures but was missing from mock-
infected cultures or cultures infected with icSARS-CoV
ORF3a (Fig. 5B). Similar results were noted with the
icSARS-CoV ORF3a/b and the icSARS-CoV ORF3&6 dele-
tion mutants. We did not see any major differences in the levels
of S glycoprotein or N protein expression (data not shown).
The murine ORF3a antiserum did not neutralize Urbani or
icSARS-CoV infectivity at a 1:50 or greater concentration.
Together, these data demonstrate that several of the accesso-
ries’ ORFs of SARS-CoV are not essential for in vitro repli-
cation.
Colocalization with S and replicase proteins. Although de-
tailed functional studies of each of the group-specific ORFs are
still ongoing, the recovery of viable viruses suggests that these
proteins do not play critical roles in regulating SARS-CoV
transcription and replication or in targeting the S glycoprotein
to particular membrane compartments essential for assembly
and release. To test this hypothesis more thoroughly, we ex-
amined the intracellular distribution of the ORF3a protein
relative to the S glycoprotein and tested whether its deletion
altered S glycoprotein localization in cell membranes. Cultures
of cells were infected with wild-type Urbani SARS-CoV and
fixed as described in the Materials and Methods at 6, 9, or 12 h
postinfection. Using antiserum directed against the nsp8 (p22)
replicase protein that is known to be associated with SARS-
CoV replication complexes (45) and murine antiserum di-
rected against the SARS-CoV ORF3a, S glycoprotein, or N
protein (prepared as described above for ORF3a), only the N
protein colocalized with SARS-CoV replicase complexes, as
evidenced by colocalization with nsp8 (p22). Neither the S
glycoprotein nor ORF3a colocalized with nsp8 (p22) replicase
proteins (Fig. 6). ORF3a distribution was punctuate and retic-
ular, consistent with a rER distribution that has been reported
by other groups (Fig. 6A) (28, 62). The S glycoprotein distri-
bution was primarily Golgi apparatus and surface membrane
expression, while N was tightly complexed with nsp8 (p22) as
well as throughout the cytoplasm of infected cells (Fig. 6B and
C, respectively).
Bioinformatic analyses and experimental studies suggest
that the SARS-CoV S glycoprotein lacks an rER localization
signal (53) and may require a chaperone protein for directing
FIG. 3. Recombinant virus growth kinetics. Cultures of Vero, MA104, or human CACO2 cells were inoculated with various recombinant or
wild-type viruses at an MOI of 1.0. Samples were taken at the indicated times and virus titers determined by plaque assay in Vero cells. (A) Growth
in Vero cells; (B) growth in MA104 cells; (C) growth in CACO2 cells. Symbols: F, Urbani SARS-CoV; E, icSARS-CoV;, icSARS-CoV ORF3a;
■, icSARS-CoV ORF3; ‚, icSARS-CoV ORF6; Œ, icSARS-CoV ORF7; }, icSARS-CoV ORF3&6.
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localization to the SARS-CoV budding compartment. To de-
termine if ORF3a altered S glycoprotein subcellular localiza-
tion, cultures of icSARS-CoV, Urbani, or icSARS-CoV 3a
were fixed and probed with rabbit antiserum directed against S
glycoprotein or murine ORF3a antiserum. As expected,
ORF3a expression is lacking from the icSARS-CoV 3a mu-
tant (Fig. 7). In agreement with earlier reports, ORF3a pri-
marily localized in rER/Golgi complexes in infected Vero cells
but was also present to a lesser extent in other membranes of
the cell. Although icSARS-CoV 3a cultures lacked ORF3a
proteins, S glycoprotein localization was not markedly altered,
retaining the intense punctuate staining in the Golgi appara-
tus/ER and surface membranes of the cell that are seen in
wild-type-infected cells. This result reduces the likelihood that
ORF3a chaperones S glycoprotein localization to particular
intracellular membrane sites associated with virion maturation
and release.
In vivo replication in mice. Deletion of one or more of the
group-specific ORFs in MHV, FIPV, and TGEV results in
marked reductions in virulence. To determine if the deletion of
SARS-CoV group-specific ORFs altered in vivo replication,
five BALB/c mice were intranasally challenged with 2 
105 PFU of Urbani, icSARS-CoV, icSARS-CoV ORF3a,
icSARS-CoV ORF3a/b, icSARS-CoV ORF6, icSARS-CoV
ORF7a/b, and icSARS-CoV ORF3&6 recombinant viruses.
At 2 days postinfection, the animals were sacrificed and virus
titers/g of lung tissue determined by plaque assay (Fig. 8A).
These data demonstrate that Urbani and the recombinant vi-
ruses replicated to titers of about 1  107 PFU/g by 2 days
postinfection. The replication of icSARS ORF3&6 to wild-
type levels in vivo differs from the noted reduction in growth
seen in in vitro cultures. Mice vaccinated twice at 0 and 28 days
with VRPs encoding ORF3a mounted robust immune re-
FIG. 4. Recombinant virus RNA synthesis. Cultures of Vero cells
were infected with various recombinant or wild-type viruses at an MOI of
1.0. Intracellular RNA was isolated as described in the Materials and
Methods and separated on 1% agarose gels. The RNA was transferred to
a BrightStar-Plus membrane (Ambion) for 4 to 5 h and the RNA cross-
linked to the membrane by UV light. The blot was probed with an
N-gene-specific oligodeoxynucleotide probe (5-CTTGACTGCCGC
CTCTGCTbTbCCCTbCTbGCb-3), where biontinylated nucleotides are
designated with a superscript b. Blots were hybridized overnight and
washed with low- and high-stringency buffers as recommended by the
manufacturer (BrightStar BioDetect chemiluminescent detection system;
Ambion). Filters were overlaid with film and developed.
FIG. 5. Expression of ORF3a in VRP and recombinant viruses.
Vero cells were infected with VRPs encoding the SARS ORF3a (VRP-
ORF3a) (A) or with various recombinant or wild-type SARS-CoV (B).
The proteins were harvested at 12 h postinfection, separated on poly-
acrylamide gels, and probed with convalescent human antiserum
#1128 from a SARS-CoV-infected patient (A) or antiserum raised
from mice inoculated with VRP-ORF3a (B).
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sponses that did not protect against SARS-CoV infection at
4 weeks postboost (data not shown).
It has been postulated that the 29-bp deletion in SARS-CoV
Urbani ORF8 is an essential alteration for enhanced patho-
genesis in humans and may function to ameliorate pathogen-
esis in animals (9). It is also possible that this alteration is
necessary for efficient replication or persistence in animals
(44). Therefore, another mutant was constructed in which the
29-bp deletion in the Urbani ORF8 gene was restored, pat-
terned after the civet cat SZ16 ORF8 sequence as a model
(icSARS-SZ16 ORF8) (Fig. 1). The icSARS-SZ16 ORF8 re-
combinant replicated efficiently in Vero cells and in rodents,
equivalent to wild-type virus (Fig. 8B), and wild-type amounts
of mRNA were detected by Northern blotting (data not
shown). RT-PCR genotyping and sequence analysis confirmed
the presence of the 29-bp insertion in the icSARS-SZ16 ORF8
genome (Fig. 8C). In mice at day 2 postinfection, icSARS-
SZ16 ORF8 replicated to wild-type levels, approaching 1 
107 PFU/g (Fig. 8A). No significant increases in the duration of
virus persistence or replication were noted, as icSARS-CoV
and icSARS-SZ16 ORF8 titers were nearly identical at similar
time points postinfection (mean 6.2  1.0  104 on day 4) and
were mostly cleared by day 7 in agreement with earlier reports
in the literature with wild-type Urbani (20% of animals had
residual virus titers of low 102 PFU/ml) (56). These data sug-
gest that an intact SZ16 ORF8 does not enhance the replica-
tion efficiency, duration of replication, or pathology of SARS-
CoV in mice, although it is not clear whether this ORF
influences pathogenesis in other animal models. Clearly,
group-specific ORFs have little impact on in vivo disease in the
mouse model.
DISCUSSION
Human coronavirus pathogenesis. Coronaviruses often cause
pneumoenteric infections, targeting both the respiratory and
gastrointestinal tracts in humans and animals, yet little is
known about the underlying molecular mechanisms governing
virulence and pathogenesis, especially in the lung. Most studies
have focused on the role of the coronavirus spike glycoprotein
in regulating tropism and virulence, and clear evidence sup-
ports an important role for spike changes in pathogenesis,
tropism, disease severity, protection from infection, and cross-
species transmission (6, 35, 70). As extensive molecular evolu-
tion was noted in the genome after emergence and spread in
human populations, SARS-CoV cross-species transmission,
virulence, and pathogenesis are likely complex and multigenic
traits (9). Consequently, SARS-CoV represents an excellent
model for studying the underlying molecular mechanisms gov-
erning human coronavirus cross-species transmission, patho-
genesis, and virulence. SARS-CoV replicates preferentially in
the lung, produces severe lower respiratory tract disease, and
replicates efficiently in vitro and in a variety of animal models.
These findings, coupled with the availability of a molecular
clone, provide the necessary infrastructure to elucidate the
genetic basis for the underlying mechanisms of human coro-
navirus pneumotropism and pathology. Importantly, the
SARS-CoV genome also encodes the largest and most com-
plex set of group-specific ORFs of any known human corona-
virus, likely encoding a rich set of functions that may modulate
replication and pathogenic outcomes.
Among the Coronaviridae, the exact function of the group-
specific ORFs is unknown. Recombinant MHV, FIPV, and
TGEV lacking one or more group-specific ORFs replicate
efficiently but are attenuated in vivo (12, 13, 71). Deletion of
ORF5a in infectious bronchitis virus also minimally impacts in
vitro growth, although in vivo phenotypes have not been re-
ported (71). Among the closely related arteriviruses, deletion
of group-specific ORFs as well as several of the minor struc-
tural proteins also minimally impacts in vitro growth (67).
Products of the group-specific ORFs might disrupt or evade
host innate immune responses, encode pro- or antiapoptotic
activities, or impact other signaling pathways that might influ-
ence disease outcomes, as has been shown with other highly
pathogenic viruses (1). Alternatively, the deletion of specific
ORFs might subtly alter the overall ratios of the upstream
subgenomic mRNAs, as the transcription attenuation model
predicts that the expression of 3-proximal mRNAs influences
the level of upstream transcripts (51).
FIG. 6. Colocalization of SARS-CoV spike, ORF3a, and nucleocapsid proteins with replicase protein. Cultures of Vero cells were inoculated
with wild-type Urbani SARS-CoV and fixed at 6 and 9 h postinfection as described in the Materials and Methods. Antisera against the SARS-CoV
S glycoprotein, nucleocapsid, and ORF3a protein were used to determine cell distributions in combination with the SARS-CoV replicase protein,
p22, by confocal microscopy as previously described (45). (A) Colocalization and distribution of the SARS-CoV ORF3a and p22 replicase protein
at 6 h postinfection. (B) Colocalization and distribution of the SARS-CoV S glycoprotein and p22 replicase protein at 6 h postinfection.
(C) Colocalization and distribution of the SARS-CoV nucleocapsid protein and p22 replicase protein at 6 h (top row) and 9 h (bottom row)
postinfection.
FIG. 7. Subcellular distribution of S glycoprotein in group-specific
ORF deletion viruses. Cultures of Vero cells were inoculated with
wild-type Urbani SARS-CoV, icSARS-CoV, or icSARS-CoV ORF3a. At
12 h, the infected cells were fixed in ice-cold 100% methanol overnight,
washed with PBS, and blocked in PBS containing 5% BSA. Cells were
washed and the coverslips incubated with mouse anti-S or ORF3a
antibody diluted 1:1,000 in PBS containing 1% BSA, 0.05% NP-40, and
2% normal goat serum. Secondary antibody was fluorescein isothio-
cyanate-conjugated anti-mouse antibody diluted 1:1,000 in PBS con-
taining 1% BSA, 0.05% NP-40, and 2% normal goat serum. Coverslips
were washed, mounted, and visualized with a Nikon Microphot FXA
Upright fluorescence microscope.
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FIG. 8. In vivo replication of recombinant SARS-CoV. Six-week-old BALB/c mice were inoculated intranasally with 50 l inoculate containing
2  105 PFU of wild-type and various recombinant viruses. At 2 days postinfection, the animals were sacrificed and virus titers in the lungs
determined by plaque assay (A). To determine if an intact ORF8 alters in vivo pathogenesis in the murine model, a recombinant virus was
constructed which included the 29 bp that fuse ORF8a/b into a single contiguous ORF. The recombinant icSARS-CoV civet SZ16 ORF8 virus
replicated as efficiently as wild-type virus in Vero cells (B), contained the appropriate 29-bp insertion by RT-PCR genotyping (C), and replicated
to similar titers as wild-type virus in BALB/c mice (A). Symbols: F, Urbani SARS-CoV; E, icSARS-CoV; , icSARS-CoV SZ16 ORF8.
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Group-specific ORF function and the murine model. In
SARS-CoV, ORF3a is a structural protein that directly inter-
acts with S and is primarily localized in the rER/Golgi appa-
ratus. ORF3a reportedly induces apoptosis following transfec-
tion and expression in cells (28, 75). It has been reported that
ORF7a is also localized in the rER/Golgi apparatus and en-
codes a proapoptotic activity that induces apoptosis via a
caspase-dependent pathway (60). The function of ORF6 is
unknown. Based on the extensive sequence analysis of SARS-
CoV isolates from the wild-type and from human patients,
ORF8 has been implicated in the in vivo replication of zoo-
notic SARS-CoV isolates as a 29-nucleotide deletion rapidly
evolved following transmission into human hosts. However, the
function of ORF8 and ORF8a/b in SARS-CoV infection has
not been established, nor have ORF8 protein products been
detected in cells.
The data from this study demonstrate that icSARS-CoV
recapitulated the wild-type Urbani strain replication pheno-
type in the murine model and in cell cultures. Similar results
were obtained with the MHV molecular clone, demonstrating
that systematic assembly of full-length cDNAs results in the
recovery of wild-type viruses that display similar in vitro and in
vivo phenotypes (55, 73, 74). Our data also demonstrate that
several SARS-CoV group-specific ORFs are nonessential for
in vitro and in vivo replication. SARS-CoV infection in the
murine model is not associated with clinical disease or pathol-
ogy and is only an in vivo replication model. Although in
humans, viral load correlates with more severe SARS-CoV
disease outcomes and death (10, 27), it is unlikely that peak
virus loads or duration of viral load in the murine model can be
correlated with possible human infection outcomes or poten-
tial virus virulence. In humans, 10-fold or greater changes in
the viral load and the duration of the viral load dramatically
influence disease outcomes (10, 27), yet in many patients, peak
pathology and clinical disease occur after the peak virus titer,
suggesting that immune responses contribute to overall pathol-
ogy and disease outcomes. Recombinant viruses lacking vari-
ous group-specific ORFs displayed only 2- to 4-fold differ-
ences in titer, indicating that these ORFs did not significantly
influence in vivo replication rates in mice sufficiently to con-
clude evidence of an attenuated phenotype. In some cell lines,
however, a few mutants displayed a10-fold reduction in titer,
suggesting an attenuated phenotype, but more detailed analy-
ses are needed. Although the ORF8 29-nt deletion event was
correlated with expansion of the SARS-CoV epidemic in hu-
mans (9), an intact SZ16 civet cat ORF8 did not alter in vitro
or in vivo replication, persistence, or the duration of the viral
load in the murine model. It is possible that more dramatic
ORF8 functions would be evident in civet cats or raccoon dogs,
natural reservoirs for SARS-CoV replication. More robust an-
imal models will likely be needed to dissect the genetic deter-
minants of SARS-CoV virulence or pathogenesis in humans.
SARS-CoV has also been demonstrated to replicate efficiently
and produce clinical disease in hamsters and ferrets. Disease
severity is more controversial in macaques, as different groups
have reported varying levels of clinical disease (19, 37, 46). It is
possible that one or more of these models may be necessary to
unravel the function of these alleles in SARS-CoV virulence
and pathogenesis. Alternatively, SARS-CoV group-specific
ORFs may function in auxiliary roles that have little impact on
disease outcomes or replication in vivo. Such findings would
not be unprecedented, as deletion of ORF4 of MHV had little
impact on in vitro replication and in vivo pathogenesis (41).
However, this possibility seems less plausible given recent find-
ings that the SARS group-specific ORF6 enhances the viru-
lence of an attenuated murine coronavirus (42). Until these
recombinant viruses can be evaluated in other models, it is
prudent to consider the SARS-CoV group-specific ORF dele-
tion viruses potentially highly pathogenic and capable of pro-
ducing equivalent levels of disease in human hosts as wild-type
viruses.
Group-specific ORF function in in vitro replication. ORF3a,
which has an rER/Golgi localization signal, is localized to the
perinuclear region of the cell and colocalized with ER and
intermediate compartment markers following virus infection
(62, 75). The ORF3a protein likely exists in both glycosylated
and nonglycosylated forms and is incorporated into virions
(28). The product of ORF3a is highly immunogenic, as indi-
cated by the fact that antiserum from patients infected with
SARS-CoV or mice inoculated with VEE replicons encoding
ORF3a readily detect ORF3a by FA and Western blot analysis.
The murine ORF3a antiserum (PRNT50 [plaque reduction
neutralization titer] 	 50; human serum #1128 PRNT50 

1:1,600) did not neutralize SARS-CoV infectivity, suggesting
that ORF3a does not contribute to the neutralizing antibody
elicited during infection. However, we did not test whether the
addition of complement enhanced ORF3a-neutralizing titers.
As ORF3a-deleted viruses replicated nearly as efficiently as
wild-type virus, it is likely that ORF3a is not essential for virion
formation, maturation, or release. This is not the first report of
a nonessential virion protein among the Coronaviridae. The I
protein of MHV, encoded internal to the nucleocapsid gene, is
also a structural protein that is not essential for virion forma-
tion; rather, viruses lacking the I ORF replicate more effi-
ciently than wild-type virus and produce similar disease in vivo
(17). The E protein of MHV, but not TGEV, is not essential
for maturation and release, although replication of MHV mu-
tants lacking the E ORF is greatly diminished compared with
wild-type virus (12, 32). During assembly of the Nidovirus
equine arteritis virus, the virion glycoproteins GP(2b), GP(3),
and GP(4) form a heterotrimeric complex in the virion but are
also not essential for efficient virion formation (67). Incorpo-
ration of these minor structural proteins into the virion is E
protein dependent, as the absence of the E protein completely
prevented the incorporation of these glycoproteins into parti-
cles.
Coronaviruses bud into the lumen of an ER-to-Golgi inter-
mediate compartment (ERGIC) (29, 30). In virus-infected
cells, the function of ORF7a remains unknown. However, its
trafficking into the ER/Golgi network, the site of coronavirus
budding and assembly, suggests a possible role in maturation
and release (40). SARS-CoV ORF7 is divided into two ORFs
designated ORF7a and -7b. Although no ORF7b product has
been described to date, ORF7a encodes a 122-amino-acid type
I transmembrane protein and structural studies reveal a com-
pact seven-stranded  sandwich similar in fold and topology to
members of the immunoglobulin superfamily (40). Sequences
encoded in the transmembrane domain and short cytoplasmic
tail mediate trafficking into the rER/Golgi apparatus. ORF7a
protein can be expressed in vitro and has been detected in vivo
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(8). Early studies have failed to demonstrate ORF7a in the
virion; however, these studies also failed to detect E protein in
virions, so additional studies are warranted (62, 75). If ORF7a
is a virion protein, our data demonstrate a luxury role in virus
assembly. Further support for a role of ORF7a in maturation
and release are evidenced by coimmunoprecipitation stud-
ies, which indicate that ORF7a interacts with ORF3a, a
protein that interacts with M, E, and S and is packaged into
virions (60).
It is noteworthy that the S and ORF3a glycoproteins likely
coevolved (75). ORF3a is predicted to form interchain disul-
fide bonds with S proteins, presumably through cysteine-rich
domains localized at the junction between the putative trans-
membrane and cytoplasmic regions of the two proteins (75).
The ORF 3a protein, which contains a tyrosine-dependent
sorting signal in its cytoplasmic domain, is expressed on the cell
surface and can be internalized. It has been suggested that
ORF3a binds S and targets its localization to specific locations
in the ER/Golgi network (61), as S lacks specific ER/Golgi
retention signals (53). Deletion of ORF3a did not result in a
significant redistribution of the subcellular localization of the S
glycoprotein from concentrated punctuate localization in the
ER/Golgi network to more diffuse or surface-staining patterns
throughout the cell. Alternatively, ORF3a may interact with
several proteins that in turn interact with the S glycoprotein
and target its localization into sites of budding. When individ-
ually expressed, both the M glycoprotein and E protein traffic
through the budding compartment, but it is not clear what
makes M and E gather in the ERGIC during infection (11, 59).
The M glycoprotein also specifically interacts with E and S and
mediates localization of these glycoproteins into the ERGIC.
At this time, it is unclear whether the subcellular localization
of the SARS-CoV E and/or M glycoprotein is altered in any of
the group-specific ORF deletion viruses.
Coronavirus group-specific ORFs may function to circum-
vent host cell innate and adaptive immune responses, as ob-
served with a wide array of other viruses (1, 43). Not surpris-
ingly, the deletion of group-specific ORFs attenuated many
coronaviruses, although at this time, the mechanism of atten-
uation is not known. In SARS-CoV, it is unlikely that any of
the group-specific ORFs play a critical role in the replication
complex, especially in light of colocalization studies that reveal
that ORF3a does not colocalize with replicase proteins that
traffic into the replication complex and that deletion of
ORF3b, ORF6, or ORF7a/b did not significantly alter in vitro
replication phenotypes. Moreover, no significant differences in
subgenomic transcription were noted among any of the dele-
tion viruses and robust in vitro and in vivo virus growth was
seen even in recombinants missing several ORFs. In contrast,
the N protein interacts with the replication complex, consistent
with other reports in the literature indicating a direct role of
the N protein in replication and transcription processes (2, 4,
45, 72). Considering these findings and evidence suggesting a
role of ORF6 in virulence (42), it seems likely that the SARS-
CoV group-specific ORFs may function in modulating the
intracellular environment for efficient virus replication or host
responses to infection. Several viral proteins act at the plasma
membrane or within the secretory pathway to alter the cell
surface expression of signaling, costimulatory, and adhesion
molecules or stimulate the rapid degradation of immune rec-
ognition molecules. Although ORF7a is reported to induce
apoptosis and inhibit cell growth following transfection in cul-
ture, deletion of ORF7a, ORF6, or ORF3a/b did not influence
cell killing, as evidenced by robust cell rounding, cytopathic
effect, and death following in vitro infection (data not shown).
Consequently, it seems likely that the proapoptotic character-
istics of SARS-CoV infection in Vero cells are mitigated by
multiple gene products. In support of this hypothesis, the N
gene is capable of inducing apoptotic cell death under condi-
tions of low serum concentration and ORF3a also may induce
apoptosis and cell death (58). Moreover, some virus-host in-
teractions are highly cell specific, further complicating the in-
terpretation of the role of specific viral gene products in cell
signaling and apoptotic cell death. Consequently, it is not sur-
prising that the deletion of ORF7a had little overall impact on
global SARS-CoV cytopathic effect, although it is possible that
more subtle differences will be noted upon more detailed
analyses. Construction of a recombinant virus containing an
ORF3a/ORF7a deletion might display a much greater reduc-
tion in cell toxicity and death. The function of ORF3b or the
presence of a specific ORF3b product in SARS-CoV-infected
cells has not been reported, although deletion of ORF3
(ORF3a and ORF3b) did not result in significant reductions in
virus replication or RNA synthesis, suggesting that the ORF3b
gene product, if it exists, mediates functions other than RNA
synthesis and in vitro replication.
SARS-CoV has renewed interest in human coronavirus patho-
genesis and is a unique model for studying the molecular mech-
anisms governing the cross-species transmission of new corona-
viruses from animal reservoirs into human populations. Among
the human coronaviruses, SARS-CoV replicates efficiently in sev-
eral experimental models, providing a novel environment for elu-
cidating the genetic determinants that influence pathogenic out-
comes in multiple species. In contrast, robust animal models for
HCV NL63 and HCV HKU1 have not been reported, although a
mouse model for HCV-229E replication and pathogenesis has
been developed (33). The murine model has provided a wealth of
data regarding vaccine efficacy and components of protective im-
munity. In this study, the in vivo replication efficiencies of the
SARS-CoV group-specific ORF deletion viruses remained un-
changed from the wild type in the murine model. Animal models
that produce severe clinical disease/death will likely be required
to unravel the critical role of the group-specific ORFs as well as
other determinants of human coronavirus pathogenesis and vir-
ulence.
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